Companies › enGene
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EG-70 (detalimogene voraplasmid) Viral vector-delivered IL-12 gene therapy for intravesical bladder instillation | IL12 | Phase 1 | Superficial Bladder Cancer | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04752722 | EG-70 (detalimogene voraplasmid) | Phase 1 | Superficial Bladder Cancer | Oncology | Apr 2028 |
Cash and short-term investments of $266m on 2026-07-31; operating cash outflow about $105m a year; runway about 30 months at that burn, to Feb 2029
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Strand Therapeutics Geneos Therapeutics Suzhou Abogen Biosciences Imunon VLP Therapeutics Sonnet BioTherapeutics Kangabio AUSTRALIA Inovio Pharmaceuticals Trogenix
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.